Dr. Richard Wright and Dr. C. Michael Gibson discuss the first peer-reviewed, real-world comparative effectiveness study of TTR stabilizers using U.S. claims data. Acoramidis was associated with a 34% lower risk of clinical worsening and a 43% lower risk of diuretic intensification compared with tafamidis.